Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HarMono-T Contrast Agent Kidney Ultrasound Study
2024-514924-17-00Phase 2Withdrawn
- Sponsor
- Solstice Pharmaceuticals
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of perflutren, sponsored by Solstice Pharmaceuticals. Primary endpoints: Occurrence of adverse reactions until 7±2 days post injection, 12-lead ECG and 2 more. Planned start Aug 2025; status: withdrawn.
02
Drugs
perflutren
Beyond the preview
Go deeper on 2024-514924-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514924-17-00.